Dolutegravir for the treatment of HIV-2 infection

Journal of Clinical Virology

Volumn 64, Issue , 2015, Pages 12-15

  Treviño, Ana ^a   Cabezas, Teresa ^b   Lozano, Ana Belén ^b   García Delgado, Rosa ^c   Force, Luis ^d   Fernández Montero, José María ^b   Mendoza, Carmen de ^a   Caballero, Estrella ^e   Soriano, Vincent ^f  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL DE PONIENTE   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL DE MATARÓ   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Dolutegravir; Drug resistance; HIV 2; Raltegravir

Indexed keywords

DOLUTEGRAVIR; RALTEGRAVIR; VIRUS RNA; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ANTIVIRAL THERAPY; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REBOUND; REGISTER; RETROSPECTIVE STUDY; SPAIN; VIREMIA; ADULT; ANTIVIRAL RESISTANCE; BLOOD; DRUG EFFECTS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MUTATION; VIROLOGY;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MALE; MUTATION; RALTEGRAVIR POTASSIUM; RETROSPECTIVE STUDIES; SPAIN; VIREMIA;

EID: 84923326472     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.01.001     Document Type: Article

References (17)

1. Faria N., Hodges-Mameletzis I., Silva J., et al. Phylo-geographical footprint of colonial history in the global dispersal of HIV-2 group A. J. Gen. Virol. 2012, 93:889-899.
2. Gottlieb G., Sow P., Hawes S., et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in HIV type 1- and HIV-2-infected individuals from Senegal, West Africa. J. Infect. Dis. 2002, 185:905-914.
3. Damond F., Bernard A., Balotta C., et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHIEV2E quality control study. J. Clin. Microbiol. 2011, 49:3491-3497.
4. Benard A., van Sighem A., Taieb A., et al. Immuno-virological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E collaboration study group. Clin. Infect. Dis. 2011, 52:1257-1266.
5. Raugi D., Smith R., Ba S., et al. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob. Agents Chemother. 2013, 57:2751-2760.
6. Smith R., Raugi D., Pan C., et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One 2012, 9:e45372.
7. Cavaco-Silva J., Abecasis A., Miranda A.C., et al. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS One 2014, 9:e92747.
8. Fernandez-Montero J.V., Barreiro P., Labarga P., De Mendoza C., Soriano V. Dolutegravir, abacavir and lamivudine as HIV therapy. Expert Opin. Pharmacother. 2014, 15:1051-1057.
9. Charpentier C., Camacho R., Ruelle J., et al. HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin. Infect. Dis. 2013, 56:1654-1658.
10. Menéndez-Arias L., Alvarez M. Antiretroviral therapy and drug resistance in HIV type 2 infection. Antiviral Res. 2014, 102:70-86.
11. Treviño A., de Mendoza C., Caballero E., et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J. Antimicrob. Chemother. 2011, 66:1484-1488.
12. Rodés B., Sheldon J., Toro C., et al. Quantitative detection of plasma HIV type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). J. Clin. Microbiol. 2007, 45:88-92.
13. De Mendoza C., Caballero E., Aguilera A., et al. HIV-2 and HTLV-1 infections in Spain, a non-endemic region. AIDS Rev. 2014, 16:152-159.
14. Clavel F., Guetard D., Brun-Vezinet F., et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986, 233:343-346.
15. Andreatta K., Miller M., White K. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J. Acquir. Immune Defic. Syndr. 2013, 62:367-374.
16. Salgado M., Toro C., Simón A., et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J. Clin. Virol. 2009, 46:173-175.
17. Treviño A., Parra P., Cabezas T., et al. Drug resistance mutations in HIV-2 patients failing raltegravir-extent of cross-resistance to dolutegravir. Antivir. Ther. 2013, 18(suppl 1):A105.